Cytokinetics Announces Call for Proposals for Its Seventh Annual Communications Grant Program
Cytokinetics (Nasdaq: CYTK) has announced its seventh annual Communications Grant Program, offering $100,000 in grants to patient advocacy organizations focused on cardiovascular diseases. The program will award five grants of $20,000 each to organizations serving the hypertrophic cardiomyopathy (HCM) and heart failure communities.
The grants aim to support increased communications, awareness building, and community engagement. Eligible organizations must be nonprofits or registered charities in the United States, Canada, Europe, or United Kingdom. The application deadline is November 4th, 2024, with recipients to be announced in January 2025.
The program seeks to bridge the funding gap for communication efforts in nonprofit patient organizations, enabling them to reach broader audiences and connect patients with available resources. Applications can be submitted online, and recipients will be required to provide an outcomes report at the end of the year.
Cytokinetics (Nasdaq: CYTK) ha annunciato il suo settimo programma annuale di grant per le comunicazioni, offrendo 100.000 dollari in finanziamenti per organizzazioni di advocacy dei pazienti focalizzate sulle malattie cardiovascolari. Il programma assegnerà cinque grant di 20.000 dollari ciascuno a organizzazioni che servono le comunità affette da cardiomiopatia ipertrofica (HCM) e insufficienza cardiaca.
I grant mirano a supportare un aumento delle comunicazioni, la sensibilizzazione e il coinvolgimento della comunità. Le organizzazioni idonee devono essere senza scopo di lucro o enti di beneficenza registrati negli Stati Uniti, Canada, Europa o Regno Unito. La scadenza per le candidature è 4 novembre 2024, con l'annuncio dei destinatari previsto per gennaio 2025.
Il programma cerca di colmare il divario di finanziamento per gli sforzi comunicativi delle organizzazioni di pazienti no-profit, consentendo loro di raggiungere un pubblico più ampio e connettere i pazienti con le risorse disponibili. Le domande possono essere submitted online e i beneficiari dovranno fornire un rapporto sui risultati alla fine dell'anno.
Cytokinetics (Nasdaq: CYTK) ha anunciado su séptimo programa anual de becas para comunicaciones, ofreciendo 100,000 dólares en subvenciones a organizaciones de defensa de pacientes enfocadas en enfermedades cardiovasculares. El programa otorgará cinco subvenciones de 20,000 dólares cada una a organizaciones que sirven a las comunidades de miocardiopatía hipertrófica (HCM) y falla cardíaca.
Las subvenciones tienen como objetivo apoyar el aumento de las comunicaciones, la construcción de conciencia y el compromiso comunitario. Las organizaciones elegibles deben ser sin fines de lucro o entidades benéficas registradas en los Estados Unidos, Canadá, Europa o Reino Unido. La fecha límite para las solicitudes es el 4 de noviembre de 2024, y los destinatarios se anunciarán en enero de 2025.
El programa busca cerrar la brecha de financiamiento para los esfuerzos de comunicación en organizaciones de pacientes sin fines de lucro, permitiéndoles alcanzar audiencias más amplias y conectar a los pacientes con los recursos disponibles. Las solicitudes se pueden enviar en línea, y se requerirá que los beneficiarios proporcionen un informe de resultados al final del año.
사이토키네틱스(Cytokinetics, Nasdaq: CYTK)는 심혈관 질환에 중점을 둔 환자 옹호 단체를 위해 100,000달러의 보조금을 제공하는 제7회 연례 커뮤니케이션 보조금 프로그램을 발표했습니다. 이 프로그램은 비대칭 심근병증(HCM) 및 심부전 커뮤니티를 지원하는 단체에 각각 20,000달러의 보조금 5개를 수여합니다.
이 보조금은 커뮤니케이션을 늘리고 인식 구축 및 지역 사회 참여를 지원하는 것을 목표로 합니다. 자격이 있는 단체는 미국, 캐나다, 유럽 또는 영국에 등록된 비영리 단체 또는 자선 단체여야 합니다. 신청 마감일은 2024년 11월 4일이며, 수혜자는 2025년 1월에 발표될 예정입니다.
이 프로그램은 비영리 환자 조직의 커뮤니케이션 노력을 위한 자금 격차를 해소하여 더 넓은 청중에게 다가가고 환자를 이용 가능한 자원과 연결할 수 있도록 합니다. 신청은 온라인으로 제출할 수 있으며, 수혜자는 연말에 결과 보고서를 제출해야 합니다.
Cytokinetics (Nasdaq : CYTK) a annoncé son septième programme annuel de subventions de communication, offrant 100 000 dollars en subventions aux organisations de défense des patients axées sur les maladies cardiovasculaires. Le programme attribuera cinq subventions de 20 000 dollars chacune à des organisations qui servent les communautés touchées par la cardiomyopathie hypertrophique (HCM) et l'insuffisance cardiaque.
Les subventions visent à soutenir l'augmentation des communications, la création de sensibilisation et l'engagement communautaire. Les organisations éligibles doivent être des organismes à but non lucratif ou des œuvres de charité enregistrées aux États-Unis, au Canada, en Europe ou au Royaume-Uni. La date limite de candidature est le 4 novembre 2024, avec l'annonce des bénéficiaires prévue pour janvier 2025.
Le programme cherche à combler le fossé de financement pour les efforts de communication des organisations de patients à but non lucratif, leur permettant d'atteindre un public plus large et de connecter les patients avec les ressources disponibles. Les candidatures peuvent être soumises en ligne, et les bénéficiaires devront fournir un rapport sur les résultats à la fin de l'année.
Cytokinetics (Nasdaq: CYTK) hat sein siebtes jährliches Kommunikationsstipendienprogramm angekündigt, das 100.000 US-Dollar an Förderungen für Patientenvertretungsorganisationen bietet, die sich auf Herz-Kreislauf-Erkrankungen konzentrieren. Das Programm vergibt fünf Stipendien in Höhe von jeweils 20.000 US-Dollar an Organisationen, die in den Bereichen hypertropher Kardiomyopathie (HCM) und Herzinsuffizienz tätig sind.
Die Stipendien sollen die Kommunikation, das Bewusstsein und das Engagement der Gemeinschaft fördern. Förderfähige Organisationen müssen gemeinnützig oder registrierte Wohltätigkeitsorganisationen in sein. Die Bewerbungsfrist endet am 4. November 2024, und die Empfänger werden im Januar 2025 bekannt gegeben.
Das Programm soll die Finanzierungslücke für Kommunikationsanstrengungen in gemeinnützigen Patientenorganisationen schließen und es ihnen ermöglichen, ein breiteres Publikum zu erreichen und Patienten mit verfügbaren Ressourcen zu verbinden. Bewerbungen können online eingereicht werden, und die Empfänger müssen am Ende des Jahres einen Ergebnisbericht vorlegen.
- Cytokinetics is offering $100,000 in grants to support patient advocacy organizations
- The program aims to improve communications and outreach for cardiovascular disease communities
- The initiative may help expand the company's presence and goodwill in the cardiovascular disease space
- None.
Program to Provide
Deadline for Applications is November 4th, 2024
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the seventh annual Cytokinetics Communications Grant Program. The program will award five grants in the amount of
“Communications and outreach are vital drivers of impact for nonprofit patient organizations, yet these efforts are often underfunded. As a result, segments of the patient community are left unaware of available resources and organizations may struggle to reach other critical audiences such as new donors or partners,” said Mary Pomerantz, Cytokinetics’ Senior Director of Patient Advocacy and Engagement. “The Cytokinetics Communications Grant Program aims to bridge this gap by funding innovative and essential initiatives that seek to amplify reach, broaden community engagement and ensure that those in greatest need are connected to the resources available to them.”
The Cytokinetics Communications Grant Program supports patient advocacy organizations in expanding their reach, awareness and community engagement by providing resources for new or crucial communications, marketing or outreach initiatives that would otherwise be challenging to implement. Funding from the Cytokinetics Communications Grant Program may help with programming or personnel, depending on each organization’s needs. The recipients of the 2024 Cytokinetics Communications Grants were the ALS Therapy Development Institute, Cardiomyopathy UK, Global Heart Hub, HeartBrothers Foundation and WomenHeart: The National Coalition for Women with Heart Disease.
Eligible organizations must have nonprofit organization or registered charity status in the United States, Canada, Europe or United Kingdom and serve the patient communities in HCM or heart failure. Organizations applying for the grant are required to submit a proposal outlining communication activities that the funding would support and the potential impact of the funding. Applications will be evaluated by a committee of representatives from Cytokinetics based on the proposal’s alignment with selection criteria. More details can be found at the application portal listed below. Recipients are responsible for providing an outcomes report to Cytokinetics to measure the impact and results of the funding at the end of the year. Applications may now be submitted online at https://www.cybergrants.com/Cytokinetics/communications_grant. The deadline to apply is November 4, 2024, and the grant recipients will be announced in January 2025. For more information on the program, including eligibility guidelines, visit https://cytokinetics.com/responsibility/grants-and-giving/.
About Cytokinetics
Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Cytokinetics is preparing for regulatory submissions for aficamten, its next-in-class cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in obstructive hypertrophic cardiomyopathy which were published in the New England Journal of Medicine. Aficamten is also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM, ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM, CEDAR-HCM, a clinical trial of aficamten in a pediatric population with obstructive HCM, and FOREST-HCM, an open-label extension clinical study of aficamten in patients with HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac muscle activator, in patients with heart failure. Additionally, Cytokinetics is developing CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for the potential treatment of HFpEF.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities of Cytokinetics’ product candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlines in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CYTOKINETICS® and the C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
Contact:
Cytokinetics
Diane Weiser
SVP, Corporate Affairs
(415) 290-7757
FAQ
What is the total amount offered in Cytokinetics' Communications Grant Program for 2024?
How many grants will be awarded by Cytokinetics (CYTK) in its 2024 Communications Grant Program?
What is the application deadline for Cytokinetics' 2024 Communications Grant Program?
Which patient communities does Cytokinetics' Communications Grant Program target?
